The European Commission has granted marketing authorization to AbbVie for the oral medication Aquipta, approving the drug for the acute treatment of migraine in adults, both with and without aura. This regulatory decision allows the pharmaceutical company to distribute the CGRP receptor antagonist across European Union member states for the immediate management of migraine symptoms.
Aquipta functions by targeting calcitonin gene-related peptide (CGRP) receptors, which play a central role in the development of migraine attacks. The European Commission’s approval follows a review of the drug’s clinical profile and its efficacy in addressing the acute onset of migraine. With this authorization, the medication joins the existing range of therapeutic options available to healthcare providers for adult patients suffering from the condition.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: June 3, 2026
發佈留言